Provectus Announces Presentation of Preliminary Results from Phase 1 Trial of PV-10® (rose bengal disodium) for Treatment of Metastatic Uveal Melanoma at ESMO I-O Congress 2019
12. Dezember 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
13 patients treated to date have received single-agent PV-10 or combination of PV-10 and standard of care checkpoint blockadeIndependent safety profiles of PV-10 and checkpoint inhibition were...
Provectus Announces PV-10® Abstract Accepted for Presentation at Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting
02. Dezember 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...
Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10
08. Juli 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Metastatic neuroendocrine tumors: Monotherapy data presentations planned. Phase 2 combination therapy trial designs with different classes of checkpoint inhibitor drugs being developed.Metastatic...